More tools:Markets·Screener·Research·Chat

MetaVia Inc. Common Stock (MTVA) Financial Statements

MetaVia Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG009YPPXS7
XNAS · usd
1.70▼ 0.05 (-2.86%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close1.75
Day's Range1.70 – 1.81
52-Week Range0.55 – 13.42
Volume37.8K
Avg Volume71.7K
Share Statistics
Shares Outstanding
Employees8
ExchangeXNAS
Listed2016-08-04
Share count as of August 3, 2026
Loading Income Statement…
Key questions about MetaVia Inc. Common Stock (MTVA)
What is MetaVia Inc. Common Stock's Market Cap?
MetaVia Inc. Common Stock's Market Cap is $11.2M, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's Enterprise Value?
MetaVia Inc. Common Stock's Enterprise Value is -$1.4M, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's EV / EBITDA?
MetaVia Inc. Common Stock's EV / EBITDA is 0.1×, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's Net Income (TTM)?
MetaVia Inc. Common Stock's Net Income (TTM) is -$14.4M, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's EBITDA?
MetaVia Inc. Common Stock's EBITDA is -$14.9M, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's Diluted EPS (TTM)?
MetaVia Inc. Common Stock's Diluted EPS (TTM) is -2.19, based on as-reported figures from SEC (XBRL) filings.
What is MetaVia Inc. Common Stock's Net Debt?
MetaVia Inc. Common Stock's Net Debt is -$12.6M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses
Research and development—
General and administrative—
Total operating expenses—
Loss from operations—
Other income (expense)
(Loss) gain from change in fair value of warrant liabilities—
Interest income, net—
Total other income—
Loss before income taxes—
Provision for income taxes—
Net loss
Loss per share of common stock, basic (in dollars per share)——
Loss per share of common stock, diluted (in dollars per share)——